Neonatal Toxoplasma Gondii IgM FEIA

Neonatal Toxoplasma Gondii IgM FEIA Specification

Origin of Medicine
India

Drug Type
Neonatal Toxoplasma Gondii IgM FEIA

Dosage
0.1 mmol/kg

Suitable For
Suitable For All

Storage Instructions
Cool and dry place

Neonatal Toxoplasma Gondii IgM FEIA Trade Information

Minimum Order Quantity
1 Piece

Supply Ability
1 Piece Per Week

Delivery Time
1-6 Week

Main Domestic Market
All India

About Neonatal Toxoplasma Gondii IgM FEIA

Labsystems Diagnostics' Neonatal Toxoplasma gondii IgM FEIA is a fluorometric enzyme immunoassay intended for the determination of IgM-class antibodies to Toxoplasma gondii in blood samples dried on filter paper. The test is intended as a primary method for screening newborns for congenital toxoplasmosis (CT).

overview

In a 5 year study in Brazil over 285 000 neonates were screened with Labsystems Diagnostics' Neonatal Toxoplasma gondii IgM FEIA and the prevalence was found to be 1/1867.

Fluorometric enzyme immunoassay for the determination of IgM antibodies to Toxoplasma gondii from dried blood spots. This is the first Neonatal Toxoplasma screening test in the world.

Technical Specifications

Neonatal Toxoplasma gondii IgM FEIA, 5 strip plates (12x8), 480 wells 61 99 802

Benefits

First Neonatal Toxoplasma screening test in the world
Quantitative results
Clinically proven performance
High sensitive µ-capture test

Early Detection of Neonatal Toxoplasma Infection

Timely diagnosis of Toxoplasma Gondii in neonates is vital for effective treatment. This FEIA test swiftly identifies IgM antibodies, helping healthcare providers intervene early and prevent potential complications. Its precision makes it indispensable in neonatal care settings across hospitals and clinics.

Reliable Quality from Indian Manufacturers

Sourced from trusted Indian manufacturers and exporters, this test adheres to international standards. Stringent quality controls ensure the assay delivers consistent and accurate results, thus supporting reliable clinical decision-making and patient care.

Simple and Safe Usage for Medical Practitioners

The Neonatal Toxoplasma Gondii IgM FEIA test is designed for straightforward use by clinical professionals. With dosage clearly set at 0.1 mmol/kg and comprehensive instructions for handling and storing, its application is both safe and efficient in medical environments.

FAQs of Neonatal Toxoplasma Gondii IgM FEIA:

Q: How is the Neonatal Toxoplasma Gondii IgM FEIA test administered in clinical settings?

A: The assay is administered by trained medical professionals in hospitals or clinics. A small blood sample is collected from the neonate and the test is performed using Fluorescent Enzyme Immunoassay (FEIA) technology to detect Toxoplasma Gondii IgM antibodies.

Q: What is the main benefit of using this test for neonates?

A: The main benefit is early detection of Toxoplasma Gondii infection, enabling timely intervention and minimizing the risk of complications associated with congenital toxoplasmosis.

Q: When should this test be performed on a neonate?

A: Testing is typically conducted if there is suspicion of congenital infection or if mothers have known or suspected Toxoplasma exposure during pregnancy. Early screening is recommended for at-risk newborns.

Q: Where should the Neonatal Toxoplasma Gondii IgM FEIA test be stored?

A: The test kit should be stored in a cool and dry place to preserve its chemical integrity and ensure accurate performance.

Q: What is the recommended dosage for this diagnostic test?

A: The standard dosage for the assay is 0.1 mmol/kg, as per the manufacturers guidance for neonatal use.

Q: Who is this test suitable for?

A: It is suitable for all neonates requiring Toxoplasma Gondii IgM antibody screening, under clinical supervision.

Q: What is the process after a positive test result?

A: If a positive result is obtained, immediate medical evaluation is advised. Further diagnostic tests and treatment initiation may be recommended based on clinical protocols.